SHL shares: your next growth investment?

The Sonic Healthcare Ltd (ASX:SHL) share price is down 6.2% since the start of 2025. It's probably worth asking, 'is the SHL share price undervalued?'
The Sonic Healthcare Ltd (ASX:SHL) share price is down 6.2% since the start of 2025. At the same time, the Pro Medicus Limited (ASX:PME) share price is 25.7% away from its 52-week high. This brief article explains why it could be worth adding SHL and PME shares to your ASX investing stock watchlist.

SHL share price in focus

Sonic Healthcare, listed in April 1987, has grown into one of the world’s largest pathology businesses, with operations spanning Australia, New Zealand, Europe, and North America.

The company provides a wide range of services, including laboratory medicine, pathology, diagnostic imaging, radiology, general practice medicine, and corporate medical services.

Sonic Healthcare is committed to prioritizing the needs of doctors and their patients, striving for medical excellence while fostering a supportive and desirable workplace.

PME shares

Pro Medicus is an established provider of radiology software for hospitals, imaging centres and healthcare groups worldwide.

The Pro Medicus suite of products centres around radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation solutions. These products support everything from patient scheduling and billing to fast medical imaging interpretations and analysis, making the company relevant at every stage of the radiology process.

The company’s flagship product is their Visage software, which allows radiologists to view large image files generated by X-rays remotely on mobile devices. This wasn’t previously possible, but it now allows diagnostic decisions to be made on-the-go with the aim of improving patient outcomes.

SHL & PME share price valuation

As a growth company, some of the trends we might investigate from SHL include revenue growth, profit growth, and return on equity (ROE). These measures can indicate the growth rates and prospects of the company, as well as their ability to generate returns from their assets.

Since 2021, SHL has grown revenue at a rate of 0.8% per year to reach $8,967m in FY24. Over the same stretch of time, net profit has fallen from $1,315m to $511m. SHL last reported a ROE of 6.8%.

Over the last 3 years, PME has increased revenue at a rate of 33.4% per year to hit $162m in FY24. Meanwhile, net profit has increased from $31m to $83m. PME’s last reported ROE was 50.7%.

Please keep in mind that context is important. These metrics give us some indication of company performance, but it’s just the start of valuing SHL or PME shares. To learn more about valuation, check out one of our free online investing courses.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #563907.

5%+ in passive income

Owen Rask’s investing report available

With bond ETFs like ASX:IAF and the S&P 500 riding high, now could be one of the best times to start earning passive income from a portfolio of shares and ETFs.

In this free analyst report, our Chief Investment Officer, Owen Rask, names 10 ASX stocks and ETFs to watch.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Skip to content